Less Is More: Destiny Phase IIb Trial Population Reduced
Move Agreed With FDA Will Speed Up XF-73 Trial
Executive Summary
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.